Pyrukynd (mitapivat) is a prescription drug that’s used to treat hemolytic anemia. Pyrukynd comes as an oral tablet. Pyrukynd is used to treat hemolytic anemia in adults who have pyruvate kinase (PK) ...
Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...
Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is currently the only approved treatment for CAD and is a ...
Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-threatening disease in which pathogenic immunoglobulin (IgG) autoantibodies attach to and destroy red blood ...
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of IMAAVY ...
Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results